PD-1/PD-L1 in cardiovascular disease.

Area of Science:

• Immunology
• Cardiovascular Research
• Oncology

Background:

• The PD-1/PD-L1 pathway is crucial for immune regulation and autoimmunity, controlling T cell activity.
• High PD-L1 expression on tumor cells suppresses immunity, leading to treatment failure in cancer.
• Anti-PD-1/PD-L1 therapies are effective in cancer, improving patient outcomes.

Purpose of the Study:

• To explore the role of the PD-1/PD-L1 pathway in coronary heart disease (CHD) and atherosclerosis.
• To investigate how PD-1/PD-L1 pathway alterations impact immune responses in cardiovascular diseases.
• To review current evidence on PD-1/PD-L1 expression changes in CHD and atherosclerosis.

Main Methods:

• Literature review of studies on PD-1/PD-L1 pathway in cancer, CHD, and atherosclerosis.
• Analysis of research investigating the impact of PD-1/PD-L1 expression levels on immune cell function.
• Synthesis of findings related to anti-PD-1/PD-L1 therapy and cardiovascular disease.

Main Results:

• Excessive PD-1/PD-L1 pathway activity suppresses T cell function and immunity.
• Low PD-1/PD-L1 expression or inhibition may accelerate immune processes in CHD.
• Altered PD-1/PD-L1 expression levels influence inflammation and plaque stability in atherosclerosis.

Conclusions:

• The PD-1/PD-L1 pathway plays a significant role in regulating immune responses in CHD and atherosclerosis.
• Dysregulation of this pathway can exacerbate cardiovascular disease progression.
• Targeting the PD-1/PD-L1 pathway may offer novel therapeutic strategies for cardiovascular conditions.